The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP)

DOI: 10.1097/ftd.0b013e31816336fd
Therapeutic Drug Monitoring, 2008, 30, 35-40.

#	Paper	IF	Citations
62	Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2008**, 32, 1453-8	5.5	37
61	Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2008**, 32, 1905-12	5.5	60
60	Dosing Atypical Antipsychotics. *CNS Spectrums*, **2008**, 13, 3-14	1.8	8
59	A proposal for a new multiaxial model of psychiatric diagnosis. A continuum-based patient model derived from evolutionary developmental gene-environment interaction. *Psychopathology*, **2009**, 42, 1-10	3.4	9
58	Genetic polymorphism of glutathione S-transferase T1 (GSTT1) and QT-interval in schizophrenia patients. *Journal of Molecular Neuroscience*, **2009**, 38, 173-7	3.3	5
57	Clinical Pharmacogenetics in Psychiatry. *Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies*, **2009**, 44, 49-55		4
56	Clinical Pharmacogenetics in Psychiatry. *Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies*, **2009**, 44, 56		
55	Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. *European Journal of Clinical Pharmacology*, **2010**, 66, 465-74	2.8	54
54	Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. *Pharmacogenomics Journal*, **2010**, 10, 20-9	3.5	83
53	Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. *Drug Metabolism Reviews*, **2010**, 42, 209-24	7	154
52	Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?. *Clinical Pharmacokinetics*, **2011**, 50, 415-28	6.2	15
51	Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. *Pharmacogenetics and Genomics*, **2011**, 21, 539-51	1.9	36
50	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. *Pharmacopsychiatry*, **2011**, 44, 195-235	2	641
49	Therapeutic drug monitoring of common antipsychotics. *Therapeutic Drug Monitoring*, **2012**, 34, 629-51	3.2	78
48	Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid. *Journal of Clinical Psychopharmacology*, **2012**, 32, 287-9	1.7	11
47	CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. *Schizophrenia Research*, **2013**, 149, 1-14	3.6	74
46	Pharmacogenetics of olanzapine metabolism. *Pharmacogenomics*, **2013**, 14, 1319-36	2.6	28

45	Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. *International Review of Psychiatry*, **2013**, 25, 509-33	3.6	54
44	Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 1115-37	5.5	24
43	Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. *Pharmacogenomics Journal*, **2013**, 13, 544-50	3.5	21
42	Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. *Human Psychopharmacology*, **2013**, 28, 205-14	2.3	31
41	Intramuscular aripiprazole in the acute management of psychomotor agitation. *Pharmacotherapy*, **2013**, 33, 603-14	5.8	18
40	Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. *International Review of Psychiatry*, **2013**, 25, 554-71	3.6	50
39	Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome. *International Review of Neurobiology*, **2013**, 112, 281-349	4.4	40
38	Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure. *Pharmacogenetics and Genomics*, **2013**, 23, 279-85	1.9	17
37	Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. *BMJ Open*, **2014**, 4, e004216	3	59
36	Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. *Pharmacology & Therapeutics*, **2014**, 141, 92-116	13.9	130
35	Use of very-high-dose olanzapine in treatment-resistant schizophrenia. *Schizophrenia Research*, **2014**, 159, 411-4	3.6	12
34	Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs. *Journal of Psychopharmacology*, **2015**, 29, 884-91	4.6	9
33	CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. *Therapeutic Drug Monitoring*, **2015**, 37, 152-60	3.2	23
32	In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism. *Drug Metabolism and Disposition*, **2015**, 43, 1806-14	4	31
31	Simultaneous quantification of olanzapine and its metabolite N-desmethylolanzapine in human plasma by liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. *Biomedical Chromatography*, **2015**, 29, 671-8	1.7	9
30	Clinical applications of CYP genotyping in psychiatry. *Journal of Neural Transmission*, **2015**, 122, 5-28	4.3	96
29	Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. *PLoS ONE*, **2016**, 11, e0148539	3.7	16
28	Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. *Human Psychopharmacology*, **2016**, 31, 83-92	2.3	10

27	Clinically Significant Interactions with Antipsychotics. **2016**, 397-421		2
26	Effects of 22 CYP2D6 Genetic Variations Newly Identified in Chinese Population on Olanzapine Metabolism in vitro. *Pharmacology*, **2016**, 98, 124-33	2.3	2
25	Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice. *Therapeutic Drug Monitoring*, **2017**, 39, 273-281	3.2	6
24	Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. *Pharmacogenomics*, **2017**, 18, 891-910	2.6	12
23	A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients. *Journal of Clinical Psychopharmacology*, **2017**, 37, 569-577	1.7	12
22	Etiopathogenesis of metabolic syndrome in schizophrenia recent findings. *Medicina*, **2017**, 53, 27-42		
21	Pathophysiology of Patients with Schizophrenia: Genetic and Environmental Factors. *Juntendo Medical Journal*, **2017**, 63, 8-16	0.1	
20	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry*, **2018**, 51, 9-62	2	473
19	Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. *British Journal of Clinical Pharmacology*, **2018**, 84, 462-476	3.8	40
18	Neurobiological Determinants of Tobacco Smoking in Schizophrenia. *Frontiers in Psychiatry*, **2018**, 9, 672	5	21
17	Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance. *Frontiers in Endocrinology*, **2018**, 9, 144	5.7	17
16	Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis. *Acta Psychiatrica Scandinavica*, **2019**, 139, 15-25	6.5	11
15	Smoking Rates and Number of Cigarettes Smoked per Day in Schizophrenia: A Large Cohort Meta-Analysis in a Japanese Population. *International Journal of Neuropsychopharmacology*, **2019**, 22, 19-27	5.8	22
14	Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects. *Therapeutic Drug Monitoring*, **2020**, 42, 325-329	3.2	3
13	Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients. *Psychiatry Research*, **2020**, 293, 113470	9.9	4
12	Segmental hair analysis of olanzapine and N-desmethyl-olanzapine in postmortem hair from mentally ill patients by LC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2020**, 190, 113510	3.5	4
11	Effects of Age, Drug Dose, and Sampling Time on Salivary Levels of Olanzapine, Quetiapine, and Their Metabolites. *Journal of Clinical Medicine*, **2020**, 9,	5.1	0
10	Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. *Frontiers in Pharmacology*, **2021**, 12, 711940	5.6	1

9	Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters. *PLoS ONE*, **2013**, 8, e65719	3.7	10
8	Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles. *Advanced Journal of Emergency Medicine*, **2019**, 3, e7	0.7	3
7	Pharmacogenetics and outcome with antipsychotic drugs. *Dialogues in Clinical Neuroscience*, **2014**, 16, 555-66	5.7	51
6	Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. *Dialogues in Clinical Neuroscience*, **2016**, 18, 323-337	5.7	26
5	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. *Frontiers in Genetics*, **2020**, 11, 491895	4.5	10
4	A review of a recently published guidelinesÓ"strong recommendation" for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine. *Mental Health Clinician*, **2019**, 9, 287-293	1.6	2
3	Influence of cyp2d6 polymorphisms on pharmacokinetics, efficacy and safety of antipsychotics. **2018**, 26-39		1
2	The influence of genetic and epigenetic factors as covariates of the tolerability and therapeutic response to olanzapine in the treatment of psychotic diseases. *Klinicka Farmakologie A Farmacie*, **2020**, 34, 63-69	0.1	
1	Pharmacokinetic Markers of Clinical Outcomes in Severe Mental Illness: A Systematic Review. **2023**, 24, 4776		0